Rep. Val T. Hoyle Sells Off Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Representative Val T. Hoyle (D-Oregon) recently sold shares of Thermo Fisher Scientific Inc. (NYSE:TMO). In a filing disclosed on October 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Thermo Fisher Scientific stock on September 23rd. The trade occurred in the Representative’s “FIDELITY ROLLOVER IRA” account.

Representative Val T. Hoyle also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Marriott International (NASDAQ:MAR) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Transdigm Group (NYSE:TDG) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of H&R Block (NYSE:HRB) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of NIKE (NYSE:NKE) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Bank of New York Mellon (NYSE:BK) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Cisco Systems (NASDAQ:CSCO) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Capital One Financial (NYSE:COF) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Pentair (NYSE:PNR) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Heico (NYSE:HEI.A) on 9/23/2025.
• Sold $1,001 – $15,000 in shares of Target (NYSE:TGT) on 9/23/2025.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $524.95 on Monday. The stock has a market cap of $198.23 billion, a PE ratio of 30.36, a price-to-earnings-growth ratio of 2.85 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $610.97. The firm’s 50-day simple moving average is $488.68 and its two-hundred day simple moving average is $447.49.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business’s revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors and hedge funds have recently modified their holdings of TMO. Vanguard Group Inc. increased its holdings in Thermo Fisher Scientific by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 33,789,164 shares of the medical research company’s stock valued at $13,700,154,000 after acquiring an additional 309,207 shares during the last quarter. Norges Bank purchased a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth $2,264,615,000. Franklin Resources Inc. grew its stake in shares of Thermo Fisher Scientific by 11.3% in the 2nd quarter. Franklin Resources Inc. now owns 4,897,546 shares of the medical research company’s stock worth $1,985,759,000 after buying an additional 498,238 shares in the last quarter. Amundi grew its stake in shares of Thermo Fisher Scientific by 5.9% in the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company’s stock worth $1,426,316,000 after buying an additional 168,197 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Thermo Fisher Scientific by 2.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 3,000,562 shares of the medical research company’s stock worth $1,216,612,000 after buying an additional 74,971 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company’s stock, valued at approximately $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 in the last three months. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on TMO shares. Hsbc Global Res cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. HSBC reiterated a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Evercore ISI increased their price target on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a report on Tuesday, October 7th. Barclays increased their price target on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Thermo Fisher Scientific in a report on Saturday, September 27th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $593.43.

About Representative Hoyle

Val Hoyle (Democratic Party) is a member of the U.S. House, representing Oregon’s 4th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

Hoyle (Democratic Party) is running for re-election to the U.S. House to represent Oregon’s 4th Congressional District. She declared candidacy for the 2026 election.

Val Hoyle was born in California and lives in Springfield, Oregon. Hoyle graduated from Merrimack High School. She earned a B.A. in political science from Emmanuel College in 1992. Her career experience includes working as a director at United Way of Lane County, a policy fellow at Wayne Morse Center for Law and Politics, and a commissioner at the Oregon Bureau of Labor and Industries. Hoyle has also worked in domestic and international sales, as well as manufacturing distribution.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.